Try our Advanced Search for more refined results

October 29, 2019

Exelixis, Inc. v. MSN Laboratories Private Limited et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 19, 2023

    Exelixis Notches Win Against MSN In Cancer Drug Patent Trial

    A Delaware federal judge on Thursday rejected MSN Laboratories' validity challenge to a patent on Exelixis Inc.'s blockbuster cancer drug Cabometyx, potentially keeping MSN's planned generic version off the market until 2026, while clearing the company of infringing a second patent.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login